To: Giroir, Brett (HHS/OASH) [sO >

Cc: Cassetti, Cristina (NIH/NIAID) (E) f OY G>; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID and Chloroquine

Importance: High

  

Brett:
Thanks for the note. | will run this by the people in our Program and get back to
you.
Best,
Tony

Cristina:
Are we or anyone else doing anything with clinical trials and chloroquine for
COVID-19? Please respond directly to ADM Giroir.
Thanks,
Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: [ "0 (6
FAX: (301) 496-4409
E-mail:[ | .b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

 

 

From: Giroir, Brett (HHS/OASH)[ CO J>
Sent: Saturday, February 29, 2020 9:31 AM

To: Fauci, Anthony (NIH/NIAID) (EJ CSC SF
Subject: COVID and Chloroquine

 

 

You know the old data and the new data. New in vitro look promising.
Do you have good visibility on the trials being conducted? Oris NIH running any of these?

Your time is precious, so 10 word response sufficient.

NIH-001058
